GRI Bio Participates in Virtual Investor KOL Connect Segment
September 18, 2024 09:00 ET
|
GRI Bio, Inc.
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey,...
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
September 06, 2024 17:00 ET
|
Univest Securities, LLC
New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,...
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 08:45 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 18:42 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
GRI Bio to Present at the 2024 European Respiratory Congress
September 04, 2024 08:45 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
August 27, 2024 11:15 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
August 01, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
July 29, 2024 16:05 ET
|
Imunon, Inc.
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
July 11, 2024 09:20 ET
|
GRI Bio, Inc.
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
Greenwich LifeSciences Set to Join Russell 2000 Index Again
June 26, 2024 07:33 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...